- Home
- ANVS vs QNCX Comparison
ANVS vs QNCX Comparison
Compare ANVS & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANVS
- QNCX
- Stock Information
- Founded
- ANVS 2008
- QNCX 2012
- Country
- ANVS United States
- QNCX United States
- Employees
- ANVS N/A
- QNCX N/A
- Industry
- ANVS Biotechnology: Pharmaceutical Preparations
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ANVS Health Care
- QNCX Health Care
- Exchange
- ANVS Nasdaq
- QNCX Nasdaq
- Market Cap
- ANVS 92.6M
- QNCX 70.4M
- IPO Year
- ANVS 2020
- QNCX 2019
- Fundamental
- Price
- ANVS $2.95
- QNCX $1.60
- Analyst Decision
- ANVS Strong Buy
- QNCX Strong Buy
- Analyst Count
- ANVS 6
- QNCX 4
- Target Price
- ANVS $29.67
- QNCX $9.50
- AVG Volume (30 Days)
- ANVS 548.9K
- QNCX 143.6K
- Earning Date
- ANVS 03-31-2025
- QNCX 03-31-2025
- Dividend Yield
- ANVS N/A
- QNCX N/A
- EPS Growth
- ANVS N/A
- QNCX N/A
- EPS
- ANVS N/A
- QNCX N/A
- Revenue
- ANVS N/A
- QNCX N/A
- Revenue This Year
- ANVS N/A
- QNCX N/A
- Revenue Next Year
- ANVS N/A
- QNCX N/A
- P/E Ratio
- ANVS N/A
- QNCX N/A
- Revenue Growth
- ANVS N/A
- QNCX N/A
- 52 Week Low
- ANVS $2.88
- QNCX $0.51
- 52 Week High
- ANVS $20.00
- QNCX $2.45
- Technical
- Relative Strength Index (RSI)
- ANVS 20.82
- QNCX 43.92
- Support Level
- ANVS $2.99
- QNCX $1.49
- Resistance Level
- ANVS $5.50
- QNCX $1.69
- Average True Range (ATR)
- ANVS 0.34
- QNCX 0.14
- MACD
- ANVS -0.18
- QNCX 0.00
- Stochastic Oscillator
- ANVS 3.59
- QNCX 46.15
About ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for advanced AD.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing innovative precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics.